diovan 3 mg/ml oraaliliuos
novartis finland oy - valsartan - oraaliliuos - 3 mg/ml - valsartaani
ritalin 10 mg säädellysti vapauttava kapseli, kova
novartis finland oy - methylphenidati hydrochloridum - säädellysti vapauttava kapseli, kova - 10 mg - metyylifenidaatti
ritalin 60 mg säädellysti vapauttava kapseli, kova
novartis finland oy - methylphenidati hydrochloridum - säädellysti vapauttava kapseli, kova - 60 mg - metyylifenidaatti
aimovig
novartis europharm limited - erenumab - migreenihäiriöt - kipulääkkeet - aimovig on tarkoitettu käytettäväksi migreenin ennaltaehkäisyyn aikuisilla, joilla on vähintään 4 migreeni päivää kuukaudessa, kun hoidon aloittamista aimovig.
beovu
novartis europharm limited - brolucizumab - märkä makuladegeneraatio - silmätautien - beovu on tarkoitettu aikuisten hoitoon neovaskulaarisen (kostean) ikään liittyvä silmänpohjan rappeuma (amd).
enerzair breezhaler
novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.
bemrist breezhaler
novartis europharm limited - indacaterol, mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - bemrist breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.
zimbus breezhaler
novartis europharm limited - glycopyrronium bromide, indacaterol (acetate), mometasone furoate - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - maintenance treatment of asthma in adults whose disease is not adequately controlled.
adakveo
novartis europharm limited - crizanlizumab - anemia, sickle cell - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.
kesimpta
novartis ireland ltd - ofatumumab - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.